IL299332A - Anti-NME antibody and method for treating cancer or cancer metastases - Google Patents
Anti-NME antibody and method for treating cancer or cancer metastasesInfo
- Publication number
- IL299332A IL299332A IL299332A IL29933222A IL299332A IL 299332 A IL299332 A IL 299332A IL 299332 A IL299332 A IL 299332A IL 29933222 A IL29933222 A IL 29933222A IL 299332 A IL299332 A IL 299332A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- treating cancer
- nme
- antibody
- metastasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044670P | 2020-06-26 | 2020-06-26 | |
| US202063046852P | 2020-07-01 | 2020-07-01 | |
| PCT/US2021/036500 WO2021252551A2 (en) | 2020-06-08 | 2021-06-08 | Anti-nme antibody and method of treating cancer or cancer metastasis |
| PCT/US2021/039291 WO2021263227A2 (en) | 2020-06-26 | 2021-06-27 | Anti-nme antibody and method of treating cancer or cancer metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL299332A true IL299332A (en) | 2023-02-01 |
Family
ID=79281989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299332A IL299332A (en) | 2020-06-26 | 2021-06-27 | Anti-NME antibody and method for treating cancer or cancer metastases |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230242678A1 (https=) |
| EP (1) | EP4172215A4 (https=) |
| JP (1) | JP2023532293A (https=) |
| KR (1) | KR20230028796A (https=) |
| CN (1) | CN116075318A (https=) |
| AU (1) | AU2021297535A1 (https=) |
| CA (1) | CA3183682A1 (https=) |
| IL (1) | IL299332A (https=) |
| WO (1) | WO2021263227A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106414726A (zh) | 2014-04-07 | 2017-02-15 | 米纳瓦生物技术公司 | 抗nme抗体 |
| EP3920693A4 (en) | 2019-02-04 | 2022-10-05 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS |
| CN116367857A (zh) | 2020-06-08 | 2023-06-30 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| KR20230028796A (ko) * | 2020-06-26 | 2023-03-02 | 미네르바 바이오테크놀로지 코포레이션 | 항-nme 항체 및 암 또는 암 전이의 치료 방법 |
| KR20250009592A (ko) | 2022-04-12 | 2025-01-17 | 미네르바 바이오테크놀로지 코포레이션 | 항-가변 muc1* 항체 및 그의 용도 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5631271A (en) | 1986-11-29 | 1997-05-20 | Serfontein; Willem J. | Methods and preparations for the treatment and prophylaxis of metabolic disturbances |
| US5874285A (en) | 1996-09-13 | 1999-02-23 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding a novel human nm23-like protein |
| US6818749B1 (en) * | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
| JP2002535656A (ja) | 1999-01-23 | 2002-10-22 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | コロイド固定化種と非コロイド構造上の種との相互作用 |
| JP5122705B2 (ja) | 1999-01-25 | 2013-01-16 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出 |
| WO2002001230A2 (en) | 2000-06-23 | 2002-01-03 | Minerva Biotechnologies Corporation | Rapid and sensitive detection of protein aggregation |
| CA2384713A1 (en) | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| JP2003535099A (ja) | 2000-05-26 | 2003-11-25 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | 化学又は生物学的事象を検出するための信号変換器としてのメタロセン |
| AU7014001A (en) | 2000-06-23 | 2002-01-08 | Minerva Biotechnologies Corp | Interaction of colloid-immobilized species with species on non-colloidal structures |
| AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
| WO2002029411A2 (en) | 2000-10-03 | 2002-04-11 | Minerva Biotechnologies Corporation | Magnetic in situ dilution |
| JP4335526B2 (ja) | 2000-11-01 | 2009-09-30 | ミナーヴァ・バイオテクノロジーズ・コーポレーション | コロイド構造体および非コロイド構造体による結合スピーシーズの検出 |
| EP1348034B1 (en) | 2000-11-15 | 2016-07-20 | Minerva Biotechnologies Corporation | Oligonucleotide identifiers |
| EP2322929B1 (en) | 2000-11-27 | 2016-04-06 | Minerva Biotechnologies Corporation | diagnostics, drug screening and treatment for cancer |
| WO2003018846A1 (en) | 2001-08-31 | 2003-03-06 | Minerva Biotechnologies Corporation | Affinity tag modified particles |
| EP1434584A2 (en) | 2001-09-05 | 2004-07-07 | Minerva Biotechnologies Corporation | Compositions and methods of treatment of cancer |
| JP2005507876A (ja) | 2001-09-05 | 2005-03-24 | ミナーバ バイオテクノロジーズ コーポレイション | 癌を治療する組成物および方法 |
| US20050163784A1 (en) | 2002-06-17 | 2005-07-28 | Valentijn Linda J. | Novel cancer therapies |
| CA2491017A1 (en) | 2002-07-03 | 2004-01-15 | Immunogen, Inc. | Antibodies to non-shed muc1 and muc16, and uses thereof |
| CA2537263C (en) | 2002-11-27 | 2017-05-30 | Minerva Biotechnologies Corporation | Techniques and compositions for the diagnosis and treatment of cancer (muc1) |
| WO2004050860A2 (en) | 2002-12-04 | 2004-06-17 | Diadexus, Inc. | Compositions, splice variants and methods relating to colon specific genes and proteins |
| JP2006517674A (ja) | 2002-12-20 | 2006-07-27 | ミネルバ バイオテクノロジーズ コーポレーション | ナノ粒子を含む光学デバイスおよび方法 |
| US20080064680A1 (en) | 2004-09-14 | 2008-03-13 | Bamdad Cynthia C | Methods for Diagnosis and Treatment of Cancer |
| DK1875244T3 (en) | 2005-03-30 | 2019-04-29 | Minerva Biotechnologies Corp | Proliferation of MUC1-Expressing Cells |
| CA2610292C (en) | 2005-03-30 | 2015-06-02 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
| CA2611728A1 (en) | 2005-06-08 | 2006-12-14 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
| WO2007072221A2 (en) | 2005-11-10 | 2007-06-28 | Aurelium Biopharma Inc. | Surface marker-directed cancer therapeutics |
| CN101652469B (zh) | 2006-12-06 | 2014-04-16 | 米纳瓦生物技术公司 | 用于鉴定和操作细胞的方法 |
| US20100254996A1 (en) | 2007-06-18 | 2010-10-07 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
| WO2009042815A1 (en) | 2007-09-25 | 2009-04-02 | Minerva Biotechnologies Corp. | Methods for treatment of cancer |
| WO2009042814A1 (en) | 2007-09-25 | 2009-04-02 | Minerva Biotechnologies Corp. | Early diagnosis and treatment of drug resistance in muc1-positive cancer |
| US11202775B2 (en) | 2007-09-25 | 2021-12-21 | Minerva Biotechnologies Corporation | Methods for treatment of cancer |
| DK2334703T3 (en) * | 2008-09-17 | 2015-10-05 | Innate Pharma | Configurations and methods for detection of tlr3 |
| US20170204191A1 (en) | 2008-10-06 | 2017-07-20 | Cynthia C. Bamdad | Muc1* antibodies |
| US20110195089A1 (en) | 2008-10-08 | 2011-08-11 | The Adminstrators Of The Tulane Educational Fund | Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens |
| WO2010042891A2 (en) | 2008-10-09 | 2010-04-15 | Minerva Biotechnologies Corporation | Method for inducing pluripotency in cells |
| US20100179213A1 (en) | 2008-11-11 | 2010-07-15 | Mirna Therapeutics, Inc. | Methods and Compositions Involving miRNAs In Cancer Stem Cells |
| SG176801A1 (en) | 2009-06-11 | 2012-01-30 | Minerva Biotechnologies Corp | Methods for culturing stem and progenitor cells |
| EP3228629A1 (en) | 2010-06-16 | 2017-10-11 | Minerva Biotechnologies Corporation | Reprogramming cancer cells |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2686418A4 (en) | 2011-03-17 | 2015-04-22 | Minerva Biotechnologies Corp | METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS |
| EP2707021B1 (en) | 2011-05-09 | 2024-02-21 | Minerva Biotechnologies Corporation | Genetically engineered growth factor variants |
| EP2768945B1 (en) | 2011-10-17 | 2022-01-05 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| US20240247229A1 (en) | 2011-10-17 | 2024-07-25 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
| WO2013123084A1 (en) | 2012-02-13 | 2013-08-22 | Minerva Biotechnologies Corporation | Method for detecting circulating fetal cells |
| CA2864872C (en) | 2012-02-24 | 2022-07-05 | Alteogen Inc. | Modified antibody in which motif comprising cysteine residue is bound |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| JP6748430B2 (ja) | 2012-07-13 | 2020-09-02 | ミネルバ バイオテクノロジーズ コーポレーション | より未分化状態への細胞の誘導方法 |
| CN111849874A (zh) | 2012-07-24 | 2020-10-30 | 米纳瓦生物技术公司 | Nme变体物种表达和抑制 |
| CN104717980A (zh) | 2012-08-14 | 2015-06-17 | 米纳瓦生物技术公司 | 干细胞增强疗法 |
| CA2886161A1 (en) * | 2012-09-29 | 2014-04-03 | The Trustees Of The University Of Pennsylvania | Veterinary composition and methods for non-surgical neutering and castration |
| US20160326263A1 (en) * | 2013-02-20 | 2016-11-10 | Minerva Biotechnologies Corporation | NME Inhibitors and Methods of Using NME Inhibitors |
| IL240695B2 (en) | 2013-02-20 | 2024-03-01 | Minerva Biotechnologies Corp | Nme inhibitors and methods of using nme inhibitors |
| TWI659210B (zh) | 2013-08-12 | 2019-05-11 | Minerva Biotechnologies Corporation | 加強腫瘤生長的方法 |
| CN106414726A (zh) | 2014-04-07 | 2017-02-15 | 米纳瓦生物技术公司 | 抗nme抗体 |
| CA2976089C (en) | 2015-02-10 | 2026-01-13 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies |
| US20170106046A1 (en) | 2015-03-03 | 2017-04-20 | Minerva Biotechnologies Corporation | Method for diagnosing and treating cancer using naive state stem cell specific genes |
| AU2016287603A1 (en) | 2015-07-01 | 2018-01-25 | Minerva Biotechnologies Corporation | Method of stem cell-based organ and tissue generation |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| JP2019515643A (ja) | 2015-09-23 | 2019-06-13 | ミネルバ バイオテクノロジーズ コーポレーション | 幹細胞分化剤のスクリーニング方法 |
| WO2018010140A1 (zh) | 2016-07-14 | 2018-01-18 | 中国科学院生物物理研究所 | I型干扰素受体抗体及其用途 |
| WO2018054240A1 (en) | 2016-09-20 | 2018-03-29 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pcsk9 antibodies |
| JP2020500031A (ja) * | 2016-10-11 | 2020-01-09 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用 |
| EP3600451B1 (en) | 2017-03-29 | 2025-12-24 | Minerva Biotechnologies Corporation | Agents for differentiating stem cells and treating cancer |
| WO2019104306A1 (en) | 2017-11-27 | 2019-05-31 | Minerva Biotechnologies Corporation | Humanized anti-muc1* antibodies and direct use of cleavage enzyme |
| WO2019126357A1 (en) | 2017-12-19 | 2019-06-27 | Minerva Biotechnologies Corporation | Agents for treating cancer and methods for identifying said agents |
| CN112272677B (zh) | 2018-02-26 | 2024-10-29 | 米纳瓦生物技术公司 | 使用抗muc1＊抗体的诊断方法 |
| US20200405832A1 (en) | 2018-03-09 | 2020-12-31 | Minerva Biotechnologies Corporation | Method for anti-muc1* car t cell stimulation |
| JP2022527144A (ja) | 2019-01-11 | 2022-05-31 | ミネルヴァ バイオテクノロジーズ コーポレーション | 抗可変ｍｕｃ１＊抗体およびその使用 |
| EP3920693A4 (en) * | 2019-02-04 | 2022-10-05 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS |
| CN116367857A (zh) * | 2020-06-08 | 2023-06-30 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| KR20230028796A (ko) | 2020-06-26 | 2023-03-02 | 미네르바 바이오테크놀로지 코포레이션 | 항-nme 항체 및 암 또는 암 전이의 치료 방법 |
| CA3183958A1 (en) | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Methods for deriving dopaminergic neurons from pluripotent stem cells |
| CN116234828A (zh) | 2020-07-29 | 2023-06-06 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| KR20250009592A (ko) | 2022-04-12 | 2025-01-17 | 미네르바 바이오테크놀로지 코포레이션 | 항-가변 muc1* 항체 및 그의 용도 |
| EP4522206A1 (en) | 2022-05-09 | 2025-03-19 | Minerva Biotechnologies Corporation | Chimeric antigen receptor and il-18 receptor compositions and methods of use therein |
| US20240261406A1 (en) | 2023-02-02 | 2024-08-08 | Minerva Biotechnologies Corporation | Chimeric antigen receptor compositions and methods for treating muc1* diseases |
-
2021
- 2021-06-27 KR KR1020237002931A patent/KR20230028796A/ko active Pending
- 2021-06-27 WO PCT/US2021/039291 patent/WO2021263227A2/en not_active Ceased
- 2021-06-27 US US18/002,832 patent/US20230242678A1/en not_active Abandoned
- 2021-06-27 JP JP2022580312A patent/JP2023532293A/ja active Pending
- 2021-06-27 EP EP21829179.7A patent/EP4172215A4/en active Pending
- 2021-06-27 AU AU2021297535A patent/AU2021297535A1/en not_active Abandoned
- 2021-06-27 CN CN202180053223.2A patent/CN116075318A/zh active Pending
- 2021-06-27 IL IL299332A patent/IL299332A/en unknown
- 2021-06-27 CA CA3183682A patent/CA3183682A1/en active Pending
-
2024
- 2024-09-20 US US18/892,093 patent/US12415868B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4172215A2 (en) | 2023-05-03 |
| AU2021297535A1 (en) | 2023-02-16 |
| US12415868B1 (en) | 2025-09-16 |
| WO2021263227A2 (en) | 2021-12-30 |
| WO2021263227A3 (en) | 2022-02-10 |
| CN116075318A (zh) | 2023-05-05 |
| EP4172215A4 (en) | 2024-11-20 |
| US20230242678A1 (en) | 2023-08-03 |
| CA3183682A1 (en) | 2021-12-30 |
| KR20230028796A (ko) | 2023-03-02 |
| JP2023532293A (ja) | 2023-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299332A (en) | Anti-NME antibody and method for treating cancer or cancer metastases | |
| IL313807A (en) | Claudin 18 antibodies and methods for cancer treatment | |
| IL273196A (en) | Claudin 6 antibodies and methods of cancer treatment | |
| PL3818086T3 (pl) | Leczenie i zapobieganie nowotworom złośliwym z zastosowaniem cząsteczek wiążących antygen HER3 | |
| IL285352A (en) | Anti-nme antibody and method of treating cancer or cancer metastasis | |
| SG11202106766SA (en) | Acute treatment and rapid treatment of headache using anti-cgrp antibodies | |
| EP4161495A4 (en) | PERSONALIZED CANCER TREATMENT METHODS | |
| IL299339A (en) | Antibodies and methods for treating claudin-related diseases | |
| EP4161970A4 (en) | ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES | |
| IL320743A (en) | A method for treating prostate cancer | |
| IL289811A (en) | A method for treating cancer | |
| IL319944A (en) | Methods of using anti-CTLA4 antibody to treat colon cancer | |
| SG11202108140SA (en) | Anti-bag2 antibody and methods of treating cancer | |
| IL307556A (en) | Cancer treatment methods using antibodies against TIGIT | |
| GB201918692D0 (en) | Treatment and prognosis of pancreatic cancer | |
| CA3262636A1 (en) | METHODS OF DETECTION AND TREATMENT OF OVARIAN CANCER | |
| HK40118254A (en) | Dlk1 antibodies and methods of treating cancer | |
| EP4339211A4 (en) | ANTI-CD300C MONOCLONAL ANTIBODY AND ITS BIOMARKER FOR THE PREVENTION OR TREATMENT OF CANCER | |
| IL312155A (en) | A method for treating cancer | |
| EP4337328A4 (en) | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER | |
| GB202014707D0 (en) | Downscaler and method of downscaling | |
| HK40117624A (en) | Cdh17 antibodies and methods of treating cancer | |
| HK40073192A (en) | Claudin18 antibodies and methods of treating cancer | |
| HK40115752A (en) | Methods of treating cancers and enhancing efficacy of gprc5dxcd3 bispecific antibodies | |
| HK40115754A (en) | Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies |